icon-folder.gif   Conference Reports for NATAP  
 
 
 
 
Renal Conf: ELBASVIR/GRAZOPREVIR TREATMENT OF HCV INFECTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 4/5: CLINICAL, VIROLOGIC, AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES IN THE C-SURFER STUDY
 
 
  Reported by Jules Levin
53rd ERA-EDTA Congress in 2016,
53rd Congress of the European Renal Association
May 21-24 Vienna, Austria
 
A Bruchfeld, D Roth, P Martin, D R Nelson, S Pol, M-C Londoņo, S Wan, J M Arduino, M Robertson, B-Y Nguyen, J Wahl, E Barr, W Greaves
 
"HCV infection in patients with advanced chronic kidney disease is associated with an increased risk of death, accelerated loss of remaining kidney function and kidney transplant failure1-3
-Patients with HCV and stage 4/5 CKD have limited HCV treatment options due to lack of safety/efficacy data for DAAs in patients with CrCl <30mL/min and poor tolerability of regimens that include ribavirin" [from Jules: the earliest possible HCV treatment should be provided, delaying therapy can only increase risk for extra
hepatic manifestations/comorbidities including kidney disease and increased risk for liver cancer (HCC). Medicaid & commercial therapy restrictions can be very harmful.]

DDW1

DDW2

DDW3

DDW4

DDW5

DDW6

DDW7

DDW8

DDW9

DDW10

DDW11